Connect with us

Are Penny Stocks Worth It? 3 to Watch This Week

Trading penny stocks is popular right now; here’s 3 you need to know about
The post Are Penny Stocks Worth It? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

3 Hot Penny Stocks to Watch in Mid-August 

Over the past week or so, penny stocks and blue chips seem to have reversed their bearish trend, indicating the potential of positive future momentum. If we look at the data, we see that the S&P 500 has gone more than 190 days without dropping below 5% from a 52-week high according to Sundial Capital Research. 

This is a positive sign for investors and the future of the economy. While speculation has been higher than ever, behind the hype, we have witnessed a record year for penny stocks and blue chips. In the most recent earnings season, most that reported blew expectations out of the water. 

[Read More] 3 Top Reddit Penny Stocks You Need to Know About

The researchers at Sundial Capital stated that “If we focus just on the price action of the most benchmarked index in the world, then 2021 compares with some of the easiest years ever for investors. Those precedents suggest further good times ahead, with worries only when larger trend indicators start to fail.” 

So, while 2021 may seem like a hard year overall, the list of penny stocks looks like it could be in good hands to succeed in the coming future. Considering this, let’s take a look at three hot penny stocks to watch in mid-August. 

3 Penny Stocks For Your Mid-August Watchlist 

  1. Outlook Therapeutics Inc. (NASDAQ: OTLK
  2. Evofem Biosciences Inc. (NASDAQ: EVFM
  3. OrganiGram Holdings Inc. (NASDAQ: OGI

Outlook Therapeutics Inc. (NASDAQ: OTLK)

Outlook Therapeutics Inc. is a biotech penny stock that develops and commercializes various products for the healthcare market. One of these products is ONS-5010, which is in Phase 3 clinical trial to treat retina diseases. In addition to its products, the company has collaboration and license agreements with various other biotech companies. Collaboration agreements in the biotech industry are one of the best ways that companies grow. This allows for increased revenue, and the ability to share costs when commercializing a compound.

On August 3rd, a very important update was released from Outlook Therapeutics. The company reported positive efficacy and safety data from its Phase 3 NORSE TWO trial of ONS-5010, also known as Lytenava.

“We are delighted with the compelling results observed in NORSE TWO, which represent a significant and potentially transformational milepost for patients suffering from wet AMD. We plan on bringing the first ophthalmic formulation of bevacizumab to market if approved.”

The President and CEO of Outlook Therapeutics, C. Russell Trenary III

To gain approval by the FDA for a product can often dramatically increase a company’s value in the market. While this is usually a highly speculative gain, it is important for investors to consider. Equally important, however, is the long-term potential of positive news surrounding a drug or trials. While it can take years to get to this stage, getting a compound approved is one of the best pieces of news that an investor can hear. Noting the above information, is OTLK stock going to make your penny stocks watchlist this week?

Evofem Biosciences Inc. (NASDAQ: EVFM)

Evofem Biosciences Inc. is a biotech penny stock that has climbed by around 4% in the past five days or so. This company creates medical products to treat women’s health-related needs. Its products include contraceptives, gels, and STD prevention treatments.

Additionally, its main product is Phexxi, which is a vaginal gel to prevent pregnancy. This is Evofem’s most successful product to date and is currently in the commercial stage. When a biotech company has a product in the commercialization stage, it often is a great sign for investors. Now that all the heavy lifting is done, it all comes down to getting the product in the hands of those who need it. 

In mid-July, the company released an early look at its second-quarter numbers for Phexxi. Very strong numbers were released in this report, including more than 7,000 healthcare providers prescribing the gel since its launch. In just the second quarter of 2021, 14,000 units of the treatment were distributed to patients. This is quite a substantial number, and one that could continue to grow as Phexxi becomes adopted by more doctors and patients alike. 

“The volume of women switching from hormonal birth control to Phexxi indicates a movement is happening. Women are seeking a healthy lifestyle and choosing Phexxi for hormone-free contraception is a natural fit.”

The CEO of Evofem, Saundra Pelletier

Now Evofem plans on reporting its full second-quarter results and corporate update on Wednesday, August 11th. This could be one of the main reasons that shares of EVFM stock have been growing in the past week. Often we will see spikes or declines in share value ahead of a balance sheet release. And, this seems to be the case right now with EVFM stock. With this in mind, is EVFM stock a contender for your list of penny stocks to watch?

Penny_Stocks_to_Watch_Evofem_Biosciences_Inc_EVFM_Stock_Chart

OrganiGram Holdings Inc. (NASDAQ: OGI)

Over the past year and a half, the cannabis industry has been on fire. Throughout the pandemic, the demand for marijuana and marijuana-related products has skyrocketed to new heights. And if you’re looking to take advantage of that, OGI stock could be worth watching. OrganiGram Holdings Inc. is a cannabis company that sells a long line of products in the marijuana industry. In its product portfolio are items such as edibles, extracts, oils, beverages, and much more. 

These products are for sale under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trailblazer brands. OrganiGram also sells medical cannabis products for the healthcare industry. Because of its placement in both the recreational and medicinal cannabis industry, OGI has the potential to benefit in the long term. 

[Read More] Penny Stocks to Buy This Week? 4 You Need to Know About

On July 15th, OrganiGram launched the Cannabis Innovators Panel. This is a cannabis consumer panel that offers insight into consumer preferences, usage occasions, and more. The online panel will reach 2,500 participants in Canada on an ongoing basis.

The SVP of Marketing and Communications, Megan McCrae said, “We have always believed that our greatest innovations reflect the unmet needs and preferences of our consumers, and engaging in an ongoing dialogue with them strengthens our ability to deliver on consumer-centric products.” YTD, shares of OGI stock are up by over 85%, and in the past 12 months by over 104%. Keeping this information in mind, will OGI make your penny stocks watchlist?

Penny_Stocks_to_Watch_OrganiGram_Holdings_Inc_OGI_Stock_Chart

Which Penny Stocks Are You Watching Right Now?

As stated earlier, 2021 is shaping up to be a banner year for investors. While times have been hard in the past few months, hopefully, things can turn around and begin to be consistently bullish.

[Read More] Blockchain Penny Stocks Rise As Bitcoin and DogeCoin Spike

And with so many penny stocks to watch right now, there are plenty of opportunities for investors to benefit. Considering all of this, which penny stocks are you watching right now?

The post Are Penny Stocks Worth It? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Spread & Containment

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Trending